Related Experiment Video
Updated: Mar 15, 2026
07:52
Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents
Published on: June 2, 2015
12.8K
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Paul E Lie1,2,3, Titus Y Lie4, Madeleine Nguyen5
1School of Medicine, Texas Tech University Health Sciences Center (TTUHSC), Lubbock, TX 79430, USA.
Healthcare (Basel, Switzerland)
|March 14, 2026
Summary
Ketamine offers rapid relief for acute suicidality, potentially bridging the treatment gap left by SSRIs. Further clinical studies are needed to validate this Ketamine Bridge Therapy for widespread adoption.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Rising suicide rates present a critical public health challenge.
- Standard SSRI antidepressants have a significant delay (2-6 weeks) in symptom relief, creating a dangerous lag period.
- Ketamine, an NMDA receptor antagonist, shows potential for rapid antidepressant effects.
Purpose of the Study:
- To explore the hypothetical framework of Ketamine Bridge Therapy for acute suicidality.
- To evaluate Ketamine's potential to mitigate the SSRI treatment delay.
- To synthesize current evidence on Ketamine's efficacy and safety in this context.
Main Methods:
- Narrative literature review.
- Searched PubMed, Google Scholar, Cochrane Library, and PsycINFO (January 2000-December 2025).
- Synthesized evidence on SSRI latency, Ketamine protocols, and post-discharge safety.
Main Results:
- Ketamine's mechanism of action (mTORC1) is faster than SSRIs, potentially shortening the delay to symptom relief.
- Controlled, subanesthetic Ketamine doses in clinical settings appear to have low abuse potential.
- Evidence suggests Ketamine may effectively bridge the gap during SSRI treatment latency.
Conclusions:
- Ketamine Bridge Therapy is a promising concept for managing acute suicidality.
- Rigorous longitudinal validation and sustained clinical studies are required before widespread adoption.
- Further research is essential to establish safety and efficacy for long-term use.
Related Concept Videos
01:30Electroconvulsive Therapy
1.7K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K
01:24Parenteral Anesthetics: Overview
865
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
865
01:28Drug Therapy
364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
364
01:19Depolarizing Blockers: Pharmocokinetics
691
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
691
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
775
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
775
01:26Psychosis: Goals of Pharmacotherapy
649
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
649